Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses frontal fibrosing alopecia as a type of Lichen planopilaris marked by gradual hair loss at the front of the scalp but reports no new clinical results.

This study found that using 3D dermal papilla spheroid models enhances extracellular matrix production and hair follicle marker expression, providing insights into hair follicle biology and potential for drug screening.

This review discusses treatment strategies for alopecia areata, emphasizing current immunomodulation approaches but reports no new clinical results.

This study found that baricitinib improved symptoms of atopic dermatitis and alopecia areata in both adults and children in real-world settings, aligning with clinical trial results, while noting low discontinuation due to adverse events and no new safety concerns.

In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

This study conducted a meta-analysis of gene expression data from alopecia areata patients, identifying 5109 differentially expressed genes and highlighting enriched pathways like JAK-STAT signaling, providing insights into the disease's pathogenesis and potential treatment targets.

This study reported that five patients with alopecia areata achieved satisfactory results using 15 mg of Upadacitinib daily after conventional treatments had failed, without experiencing adverse events.

In this study, 27 pediatric patients with alopecia areata treated with methotrexate showed statistically significant improvement in hair regrowth between 12-15 months, suggesting the medication's delayed but effective results, though common side effects included mood changes and gastrointestinal discomfort.

This book overview summarizes advances in integrative dermatology without presenting any new research findings.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This systematic review found that Janus kinase inhibitors have shown beneficial effects for psoriasis and alopecia areata, with promising preliminary results in other skin conditions, though more research is needed to define dosing and safety profiles.

This review discusses the efficacy and safety of topical JAK inhibitors for inflammatory skin conditions, reporting modest benefits in psoriasis and atopic dermatitis but mixed results for vitiligo and inconclusive data for alopecia areata.

This review discusses emerging treatments and mechanisms for alopecia, highlighting potential therapies like janus kinase inhibitors and advances in stem-cell technology, but reports no new experimental results.

In this study, deuruxolitinib and baricitinib showed promising efficacy in treating alopecia areata, but effectiveness varied with dosage and further trials are needed to confirm these results.

This case report describes a 14-year-old girl with alopecia universalis and mild atopic dermatitis who achieved complete hair regrowth and eczema resolution after three months of treatment with the JAK1 inhibitor upadacitinib.

This study found that US adolescents with alopecia areata, especially those with alopecia totalis or universalis, experience significantly higher healthcare costs and resource use compared to matched controls.

This review discusses the economic burden of alopecia areata in adolescents and reports no new results; the authors note that evidence in this area is limited.

This review discusses recent advances in the treatment of alopecia areata, highlighting new potential therapies like JAK inhibitors and PRP, and reports no new clinical results.

This study describes a new treatment algorithm for alopecia areata that includes both disease severity and quality-of-life considerations, highlighting recent therapeutic advances and the need for future validation and access equity.

In this case report, researchers describe a 44-year-old woman with refractory patch alopecia areata achieving complete hair regrowth using a multi-modal approach of systemic and topical cholecalciferol with microneedling, although systemic vitamin D repletion remains a significant confounder.

Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.

This phase 2a trial evaluated Samcyprone for common wart treatment and found that while a sensitization reaction is necessary for therapeutic response, its level does not predict wart clearance.

This study found that treating human skin explants with TPA increased the number of certain melanocyte phenotypes in the interfollicular epidermis, suggesting that this ex vivo model can effectively replicate human skin's pharmacologic responses for studying potential treatments.

This review discusses the emerging use of JAK inhibitors in alopecia areata treatment and reports no new clinical results; it highlights hair regrowth despite symptom recurrence after stopping therapy.

This review highlights the potential of ginseng and its metabolites in preventing hair loss, detailing their hair growth-promoting effects observed in numerous preclinical studies, and emphasizing the underlying mechanisms involved.

This review examines the potential of bimatoprost for treating various types of eyelash and eyebrow hypotrichosis, discussing its pharmacological properties but providing no new clinical results.

This article discusses the role of interleukin-15 and Janus kinase inhibitors in alopecia areata based on a murine model and reports no new experimental results.

This study observed that patients with alopecia areata often have comorbidities and experience significant healthcare costs, with treatments like systemic therapies being infrequently used.

This review examines microneedle patches for drug delivery, detailing their designs, materials, manufacturing methods, and potential advantages, but reports no new clinical results.